Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 12,635

Document Document Title
WO/2020/001475A1
This invention relates to phosphorus-containing prodrugs of gemcitabine and their use in the treatment of cancer and viral infectious diseases. Compared with the parent drug (i.e., Gemcitabine), the prodrugs of present invention show a s...  
WO/2019/191389A4
The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvate...  
WO/2020/006157A1
Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein DOT1L to induce degradation of...  
WO/2019/246289A1
Methods, devices, reagents and kits designed to improve the performance of proteomic based assays are provided. Such methods have a wide utility in proteomic applications for research and development, diagnostics and therapeutics by prov...  
WO/2019/246403A1
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.  
WO/2019/237297A1
An improved process for preparing the compound (I) is provided: which may be used in the synthesis of e.g. AL-335; AL-355 is a nucleoside inhibitor of NS3B polymerase, which plays an important role in the replication of the hepatitis C v...  
WO/2019/236777A1
The invention provides methods of monitoring development of renal inflammation in a subject following administration of a nephrotoxic agent. The methods involve analyzing levels of one or more UDP-hexoses, such as UDP-glucose, UDP-galact...  
WO/2019/227526A1
Provided is a fluorescently labelled nucleotide having a structure represented by formula I. The fluorescently labelled nucleotide is linked by a covalent bond between deoxyribonucleoside triphosphate and a fluorescent dye molecule and i...  
WO/2019/228319A1
The present invention belongs to the field of medical technology and relates to an intestinal MCT1 carrier protein design-based prodrug and a preparation method therefor, and in particular relates to a preparation method for a short-chai...  
WO/2019/226952A1
An oligo- or polynucleotide analogue having one or more structures of the general formula: where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is used for treating obesity-related metabolic diseases.  
WO/2019/226755A1
The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein M1, R1, R2, and R3 are a...  
WO/2019/224172A1
The present invention relates to the manufacture of allofuranose from glucofuranose as defined in the description and in the claim. Allofuranos is an intermediate in the manufacture of oligonucleotides which can be used as a medicament.  
WO/2019/219070A1
The present invention belongs to the field of medicinal chemistry and relates to a deuterated oligonucleotide and a prodrug. In particular, the present invention relates to a compound represented by formula I or a pharmaceutically accept...  
WO/2019/219895A1
The present invention relates to crystalline (thio)nicotinamide ribofuranoside salts, methods of making such crystalline salts, a pharmaceutical composition comprising same, and use of said crystalline salts as nutritional (dietary) supp...  
WO/2019/221024A1
[Problem] To develop a purine base derivative. [Solution] A guanosine derivative compound characterized by being represented by the formula, wherein one of R1 and R2 is H and the other is any of H, OH, OCH3, and F, R3 is any of a compoun...  
WO/2019/222368A1
The present invention relates to amino acid salts of nicotinic acid mononucleotides and nicotinamide mononucleotides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in...  
WO/2019/222500A1
Methods of modulating the activity of a cyclic dinucleotide (CDN) in a cell via membrane transporter are provided. Aspects of the methods may include contacting a cell with a CDN transporter-modulating agent to modulate transport of a CD...  
WO/2019/217470A1
Automated oligonucleotide synthesis-compatible sulforhodamine dye phosphoramidite compounds and labeled polynucleotides incorporating these dyes are provided.  
WO/2019/213756A1
Compounds are described which include polyvalent ligands linked to a cyclodextrin scaffold which exhibit strong binding affinities for lanthanides and favorable characteristics with respect to altering the relaxation time of coordinated ...  
WO/2019/211799A1
The present disclosure relates to 2'3'-cyclic dinucleotides comprising a carbocyclic nucleotide and derivatives thereof, that can modulate the activity of the STING adaptor protein.  
WO/2019/204869A1
The present invention relates to improved prodrugs, and compositions thereof. In particular, it relates to amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid c...  
WO/2019/209840A1
Provided herein are methods and compositions related to treating and/or preventing rheumatoid arthritis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide ribosi...  
WO/2019/208571A1
The present invention provides: an amidite compound represented by formula (1), which enables synthesis of RNA with high purity; and a method for producing a polynucleotide, which uses this compound. (In the formula, R represents a group...  
WO/2019/178393A9
The invention provides various orthogonal nucleotide analogues and methods for using combinations of said various orthogonal nucleotide analogues for sequencing by synthesis.  
WO/2019/200273A1
The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.  
WO/2019/194385A1
The present disclosure relates to a method and apparatus wherein terahertz waves including a first band corresponding to methylation resonance frequency in the terahertz band are applied to methylated molecules and the methylated molecul...  
WO/2019/193543A1
The present invention relates to 3'3'-cyclic dinucleotides modified with a 3'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (I) or a pharmaceutically acceptable salt thereof wher...  
WO/2019/195494A1
The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.  
WO/2019/193542A1
The present disclosure relates to 2'3'-cyclic dinucleotides modified with a 2'- or 3'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (IA) or a compound of Formula (1B) or pharmace...  
WO/2019/193533A1
The present invention relates to 2'2'-cyclic dinucleotides modified with a 2'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (I) or pharmaceutically acceptable thereof, wherein L1...  
WO/2019/191642A1
Provided herein are methods and labeling kits for synthesizing 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyl-u racil in a one-pot reaction in compliance with CGMP. Also disclosed are labeling kits that can be assembled in an...  
WO/2019/191389A1
The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvate...  
WO/2019/185477A1
Compounds of formula I, wherein Base, R1 and R2 are defined as in claim 1, are modulators of STING.  
WO/2019/175126A1
The invention comprises LNA-dicarboxylic acid derivatives of the formula I or salts thereof, wherein R1 is a nucleobase or a modified nucleobase R2 is a hydroxy protecting group and n is an integer from 1 to 5. The LNA-dicarboxylic acid ...  
WO/2019/175776A1
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2019/178393A1
The invention provides various orthogonal nucleotide analogues and methods for using combinations of said various orthogonal nucleotide analogues for sequencing by synthesis.  
WO/2019/174657A1
Substituted pyridopyrrolopyrimidine ribonucleosides of general formula I, wherein R is as described in the independent claim, preferably R is selected from the group comprising thiophen-3-yl, furan-2-yl, furan-3-yl, benzofuran-2-yl, meth...  
WO/2019/169837A1
The invention relates to an albumin conjunction-type maleimide functionalized gemcitabine prodrug as well as application thereof in transferring an antitumor prodrug. The albumin conjunction-type maleimide functionalized gemcitabine prod...  
WO/2019/172394A1
A β-modified phosphoric acid compound precursor having the partial structure represented by formula 1A in the molecule thereof. A medicine and a reaction inhibitor containing the β-modified phosphoric acid compound precursor. (In the f...  
WO/2019/173682A1
Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions com...  
WO/2019/171285A1
The invention relates to compounds of Formula (I), vvherein R1 is selected from the group consisting of: Formula (Ia) and (Ib) as well as methods of treating or preventing HIV in subjects.  
WO/2019/166457A1
The disclosure relates to tagged nucleoside compounds comprising a nucleotide polyphosphate covalently attached to a tag, wherein the compound is a polymerase substrate and the polymer moiety is capable of entering a nanopore linked to t...  
WO/2019/160059A1
Provided is a method for recycling s-adenosylmethionine that is characterized in that after s-adenosylmethionine is demethylated, s-adenosylmethionine is regenerated by converting s-adenosylmethionine from methionine obtained by transfer...  
WO/2019/160994A1
Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane...  
WO/2019/160937A1
A labeled nucleotide includes a nucleotide, a linking molecule attached to a phosphate group of the nucleotide, and a redox-active charge tag attached to the linking molecule. The redox-active charge tag is to be oxidized or reduced by a...  
WO/2019/155639A1
The present invention relates to a production method and a production intermediate for guanosine-3',5'-bisdiphosphate.  
WO/2019/156240A1
The present invention relates to a production method and a production intermediate for guanosine-3',5'-bisdiphosphate.  
WO/2019/154388A1
The present application relates to a salt of a pyranose-substituted heterocyclic compound, a preparation method therefor, and use thereof, and in particular, to an acid addition salt of a compound of formula (I) or a prodrug thereof, and...  
WO/2019/152911A1
Disclosed are compounds having formula (I) or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6, and Effector are each as defined in the specificatio...  
WO/2019/152416A1
Provided herein are compounds of Formula (I) and their salts, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the disclosed compounds and composit...  

Matches 151 - 200 out of 12,635